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Abstract:  There  is  an  urgent  need  for  new  antibiotics  to  treat  hospital-  and  
community-associated  methicillin-resistant  Staphylococcus  aureus  (MRSA)  infections. 
Previous  work  has  indicated  that  both  terrestrial  and  marine-derived  members  of  the 
napyradiomycin class possess potential anti-staphylococcal  activities. These compounds 
are unique meroterpenoids with unusual levels of halogenation. In this paper we report the 
evaluation  of  two  previously  described  napyradiomycin  derivatives,  A80915A  (1)  and 
A80915B  (2)  produced  by  the  marine-derived  actinomycete,  Streptomyces  sp.  strain  
CNQ-525, for their specific activities against contemporary and clinically relevant MRSA. 
Reported are studies of the in vitro kinetics of these chemical scaffolds in time-kill MRSA 
assays. Both napyradiomycin derivatives demonstrate potent and rapid bactericidal activity 
against contemporary MRSA strains. These data may help guide future development and 
design  of  analogs  of  the  napyradiomycins  that  could  potentially  serve  as  useful  
anti-MRSA therapeutics. 
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1. Introduction 
The rapid rise of methicillin-resistant Staphylococcus aureus (MRSA) infections worldwide has 
defined an urgent need for new antibiotics. MRSA is now the most common cause of skin and soft 
tissue infections in the United States [1], and both community-associated (CA) and hospital-associated 
(HA) strains of MRSA pose a great challenge to human health. This problem is compounded by the 
de-emphasis of antibiotic screening programs in pharmaceutical companies over the last 20 years, with 
only a few novel antibiotic scaffolds introduced as therapeutics over the last decade [2,3]. 
Most  of  the  antibiotics  used  in  the  clinic  today  are  derived  from  secondary  metabolites  from 
actinomycete bacteria of terrestrial origin [4]. This group of filamentous spore-forming bacteria have 
yielded  a  great  number  of  today’s  clinical  therapies,  including  the  commonly  used  antibiotics 
gentamicin, rifampin and vancomycin [4,5].  
In 1986, a novel antibiotic class was discovered from the soil-derived organism Chainia rubra 
MG802-AF1  in  Japan  [6,7].  This  class  of  meroterpenoid  dihydroquinone  compounds,  termed 
napyradiomycins, was initially characterized according to their physiochemical, spectroscopic, NMR 
and X-ray diffraction properties [8,9]. In 1990, another actinomycete, Streptomyces aculeolatus, was 
found  to  produce  structurally  related  napyradiomycins  [10–14].  Early  assays  revealed  the 
napyradiomycin class to have significant activities against Gram-positive bacteria including S. aureus, 
S. epidermidis, Enterococcus faecalis and E. faecium, Streptococcus pyogenes and S. pneumoniae, 
Haemophilus influenzae, Bacillus anthracis, and Micrococcus luteus [6,9,10,12]. Napyradiomycins, 
including  A80915A  (1)  and  A80915B  (2),  showed  activity  against  Clostridium  difficile  and 
C. perfringens and other anaerobic bacteria; however, no activity was found against Gram-negative 
bacteria [10].  
Over the last decade, research has focused on the discovery and characterization of natural products 
from marine-derived actinomycetes [5,15]. Fenical and colleagues recently isolated the marine-derived 
actinomycete strain, CNQ-525, that was found to be a member of the MAR 4 group of Streptomyces 
related bacteria [15–18]. This strain was also found to produce chlorine-containing meroterpenoids of 
the napyradiomycin class [17,18]. Through cultivation and fractionation, numerous napyradiomycin 
analogs  were  collected  and  initial  bioactivities  of  these  compounds  were  tested.  Similar  to  the 
previously discovered napyradiomycins, the majority of these marine-derived derivatives were found 
to have both antibacterial and cytotoxic activities [17,18]. 
As clinical strains of MRSA become increasingly resistant to antibiotics, there is a clear need for 
the discovery of new antibiotics that can treat complicated infections caused by these strains. In this 
paper,  we  evaluate  the  antibacterial  activity  effects  of  two  previously  described  napyradiomycin 
compounds (1) and (2) against a contemporary and clinically relevant panel of HA- and CA-associated 
strains  of  MRSA,  two  vancomycin-resistant  (VRSA),  and  a  panel  of  glycopeptide-intermediate 
S. aureus  (GISA)  strains.  Additionally,  we  assess  key  pharmacological  characteristics  of  these Mar. Drugs 2011, 9  
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compounds using an in vitro time-kill kinetic assay. Our data illustrate that select napyradiomycins, 
while cytotoxic, are also potent anti-MRSA antibiotics with rapid in vitro time kill kinetics. 
2. Results and Discussion 
The actinomycte strain CNQ-525 was isolated and cultured from a marine-sediment collected at 
152  m  depth  off  the  coast  of  La  Jolla,  CA,  USA.  This  strain  was  subjected  to  16S  rRNA  
sequence  analysis  and  found  to  be  part  of  the  MAR  4  group  that  is  within  the  family 
Streptomycetaceae [16,17,19]. This strain has been identified as a prolific producer of halogenated 
MAR 4 derivatives. Two of these compounds, 1 and 2 (Figure 1), were purified from extracts of the 
saline cultures of strain CNQ-525.  
Figure 1. Structures of two napyradiomycins 1 and 2 isolated from the marine-derived 
actinomycete strain CNQ-525 and earlier from S. aculeolatus [10]. 
 
More recently, we observed that napyradiomycins from the marine strain CNQ-525 could show 
activities  against  a  test  strain  of  MRSA  and  vancomycin-resistant  Enterococcus  (VRE)  [17].  
We investigated in detail the antibiotic properties of napyradiomycins against a panel of clinically 
relevant MRSA strains. Minimum inhibitory concentration (MIC) assays were preformed using broth 
microdilution  assays  and  our  results  show  that  both  napyradiomycins  1  and  2  possess  potent  
anti-MRSA activities against a series of HA- and CA-MRSA strains, two VRSA strains and a series of 
glycopeptide-intermediate  (GISA)  strains  (Table  1).  For  1,  the  MIC  was  ~2  µg/mL  against  the  
CA-MRSA strains UAMS-1182 and TCH1516, both isolates of the USA300 clone currently epidemic 
in the U.S. Similarly, against the same strains the diazoketone 2 showed slightly more potent activities 
with MIC values averaging 1.5 µg/mL. Against HA-MRSA strains, both compounds exhibited MICs 
in the range of 1–3 µg/mL. The napyradiomycins retained their activities against the Michigan and 
Pennsylvania VRSA isolates as well as against GISA strains with overall MICs ranging from 0.5 to 
4 µg/mL. 
We  studied  the  time-kill  kinetics  of  1  and  2  at  two  different  concentrations,  compared  to 
vancomycin and gentamicin. In vitro time-kill analyses were conducted at 1×  and 10×  of derivative 1, 2, 
vancomycin or gentamicin control against CA-MRSA USA300 (TCH1516) (Figure 2A–C) and against 
the HA-MRSA Sanger 252 (Figure 2D–F). Over the first 4 h, the bactericidal activity for the two 
napyradiomycins 1 and 2 was more rapid than that observed for the vancomycin control and more Mar. Drugs 2011, 9  
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closely paralleled the kinetics seen in the gentamicin controls (Figure 2C,F). Cultures incubated with 
10×  MIC of 1, 2 or gentamicin showed complete killing at 2 h. Cultures treated with 1×  MIC of 1 
showed a nearly two-log reduction in bacterial counts at 4 h. The diazoketone derivative 2 showed 
slightly more potent and rapid killing with nearly a four-log decrease in bacterial counts at just 2 h in 
1×   MIC  treated  cultures.  Vancomycin  treated  cultures  showed  time-dependent  kinetics,  with  no 
difference in bacterial counts between the 10×  and 1×  treated cultures over the first 4 h.  
Table  1.  Minimum  Inhibitory  Concentrations  (µ g/mL)  of  napyradiomycins  against 
contemporary antibiotic-resistant Staphylococcus aureus strains.  
Strain  Compound 1  Compound 2 
S. aureus ATCC 29213  2  4 
MRSA-ATCC33591 
a  1–2  2 
NRS70 (N315) 
a  1  2 
Sanger 252 
a  1–2  1 
NRS100 (COL) 
a  1  2 
MRSA clinical bacteremia isolate c-44 
a  3  1.5 
MRSA clinical bacteremia isolate c-88 
a  1.5–3  1.5 
MRSA USA300 (UAMS1182) 
b  1.5–3  1–3 
MRSA USA300 (TCH1516) 
b  2  1–2 
VRSA (Michigan Isolate)  1–2  2–4 
VRSA (Pennsylvania Isolate)  1–2  4 
GISA (HIP5836) (New Jersey) 
c  0.5  1 
GISA (PC-3) (New York) 
c  0.5  1 
Hetero-GISA A5940 
c  1  4 
a HA-MRSA strains; 
b CA-MRSA strains; 
c Sakoulas et al. [20].  
Napyradiomycins  1  and  2  (A80915A  and  A80915B)  share  similar,  but  not  identical,  structural 
features  (Figure  1).  The  main  difference  between  these  two  derivatives  is  the  existence  of  a 
diazoketone functionality attached to the napthoquinone core (Figure 1B). Common to both of these 
scaffolds is the existence of a methyl group at the C16 position and the exocyclic methylene group 
at C1. Interestingly, the original napyradiomycins isolated by Shiomi et al. [6–9] lacked this C16 methyl 
group, however, the compounds extracted by Fukuda et al., contained this methyl feature [10].  
This structural-activity relationship (SAR) data can be of importance in designing new derivatives 
as  antibiotic  candidates.  For  example,  the  C16  methyl  group  of  A80915A  (1)  has  been  found  to 
slightly reduce the cytotoxic activity in comparison to a napyradiomycin lacking the methyl group 
(Farnaes  et  al.  [21]).  Using  an  antiproliferative  bioassay,  we  quantified  the  cytotoxicity  of 
napyradiomycins 1 and 2 using HCT-116 human colon adenocarcinoma cells. Our results revealed a 
low  therapeutic  index  for  both  compounds.  IC50  values  for  compounds  1  and  2  were  3  µM  and 
500 nM,  respectively.  These  results  correlate  with  the  studies  of  Fukuda  et  al.,  which  previously 
showed that in napyradiomycin derivative A80915B (2) the diazoketone group increased mammalian 
cell cytotoxicity [10]. Furthermore, our time kill analyses show that both the diazoketone derivative 
and 1 have effective bactericidal killing, even at 1×  MIC (Figure 2). Though the diazoketone 2 may 
appear to have more rapid kinetics, compound 1 has similar kinetics. With this structure information in Mar. Drugs 2011, 9  
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hand, it is conceivable that the napyradiomycin scaffold could be modified to contain structural moieties 
that reduce mammalian cell cytotoxicity yet retain or enhance anti-MRSA activities we report here. 
Figure  2.  In  vitro  time-kill  studies  of  A80915A  (1A,D);  A80915B  (2B,E);  conrols 
vancomycin and gentamicin (C,F) against CA-MRSA TCH1516 (A–C) and HA-MRSA 
Sanger 252 (D–F).  
 
In  addition  to  achieving  reduced  cytotoxicity  and  enhanced  antibiotic  activities,  further 
development of napyradiomycins as viable anti-MRSA drug candidates would also involve optimizing 
compound bioavailability. A recent study on terpenoids produced by actinomycetes compared various 
napyradiomycin scaffolds and revealed that the antibacterial activities were greatly diminished in the 
presence  of  horse  serum  [22]. We  confirmed  these  results  against  the  CA-MRSA  USA300  strain 
TCH1516 using a resazurin-based color change broth microdilution MIC assay to assess for bacterial 
growth in the presence of serum. Our results show that in the presence of 20% normal human serum, 
the  activity  of  napyradiomcyins  is  abolished.  These  results  highlight  a  critical  obstacle  in  the 
development of napyradiomycin analogs as clinical anti-MRSA therapeutics. Focused SAR studies  
of the napyradiomycin scaffold could conceivably identify a compound with activity in the presence  
of  serum.  Alternatively,  the  current  napyradiomycin  derivatives  could  be  contemplated  for  
topical applications.  
Napyradiomycins  have  been  described  as  novel  terpenoids  with  promising  broader  therapeutic 
application [23]. This novel scaffold has generated recent interest in both its biosynthetic pathway [24] Mar. Drugs 2011, 9  
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as well as in possible chemical syntheses [25]. The study of the molecular biosynthetic gene cluster 
associated with strain CNQ-525 has revealed that napyradiomycin biosynthesis involves polyketide 
pathways, halogenation, terpenoid biosynthetic pathways and chloronium ion-induced cyclization via a 
vanadium-dependent  chloroperoxidase  [24].  Terpenoid  biosynthesis  stems  from  a  mevalonate 
pathway. Besides napyradiomycins, various marine-derived secondary metabolites are biosynthesized 
through a mevalonate pathway. For example, oxaloterpin, naphterin, terpentecin, and other terpene 
containing scaffolds are produced by actinomycetes with a mevalonate pathway [22,23]. 
3. Experimental Section 
3.1. Isolation and Cultivation of CNQ-525 and Purification of Napyradiomycin Derivative 1 (A80915A) 
and Derivative 2 (A80915B) 
The actinomycete strain CNQ-525, identified as a member of the MAR 4 clade (related to the genus 
Streptomyces) was isolated from a marine sediment collected at a depth of 152 m near La Jolla, CA, 
USA.  Procedures  detailing  the  isolation  and  cultivation  of  this  strain  and  the  purification  of 
napyradiomycin compounds were previously published [17]. Briefly, strain CNQ-525 was cultivated 
by shaking at 30 ° C for 7 days in liquid nutrient media (10 g starch, 4 g yeast extract, 2 g peptone,  
1 g CaCO3, 5 mL of 0.8% (w/v) Fe2SO4· 4H2O stock solution in 1 L of seawater). Cultivation was 
followed by extraction using an Amberlite XAD-7 resin for 6 h, filtration and extraction by acetone. 
The crude whole culture extract was separated by silica gel and Flash chromatography using ethyl 
acetate and iso-octane into ten fractions with differing polarities. Subsequently, the fractions were 
analyzed by LCMS, and compounds 1 and 2 were isolated by HPLC and analyzed for weight and 
purity prior to antibacterial assays. Compounds 1 and 2 were dissolved in DMSO, protected from light, 
and stored at −20 °C. Fresh samples were thawed immediately prior to each assay. 
3.2. Bacterial Strains 
A panel of HA- and CA-MRSA strains were used to evaluate the activity of napyradiomycins 
against contemporary and clinically relevant strains of MRSA. These strains included ATCC33591, 
NRS70 (N315), Sanger 252, NRS100 (COL), an MRSA clinical isolate designated #44 and a second 
clinical  isolate  designated  #88,  as  well  as  UAMS1182  and  TCH1516  (both  USA  300  strains). 
In addition, the methicillin-sensitive (MSSA) strain ATCC 29213, a susceptible reference strain of 
S. aureus,  was  included  in  the  panel.  To  further  evaluate  napyradiomycins  against  multiresistant 
S. aureus strains, we tested a panel of glycopeptide-intermediate (GISA) and two vancomycin-resistant 
(VRSA) strains, including HIP5836 (GISA, New Jersey, U.S.), A5940 (Hetero-GISA), PC-3 (GISA, 
New York, U.S.), and VRSA (Michigan, U.S.) and VRSA (Pennsylvania, U.S.). Isolates with the NRS 
designation  were acquired via the  Network of  Antimicrobial Resistance in  Staphylococcus  aureus 
(NARSA)  program  (supported  under  NIAID/NIH  contract  HHSN272200700055C).  The  USA300 
isolate  was  obtained  from  Greg  Somerville  at  the  University  of  Nebraska,  Lincoln  and  originally 
received from Mark Smeltzer at the University of Arkansas Medical Center. The second USA300 
isolate, TCH1516 (ATCC BAA-1717) and the HA-MRSA strain ATCC 33591 were obtained from the 
American Type Culture Collection (Manassas, VA, U.S.). Michigan and Pennsylvania VRSA strains, Mar. Drugs 2011, 9  
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the panel of GISA strains, and the two MRSA clinical bacteremia isolates were obtained from George 
Sakoulas, MD, USA (University of California San Diego). 
3.3. Susceptibility Testing 
Minimum inhibitory concentration (MIC) assays were performed by broth microdilution according 
to CLSI guidelines [26]. Vancomycin (Hospira, Lake Forest, IL, USA) or gentamicin sulfate (Hospira, 
Lake Forest, IL, USA) were the MRSA control antibiotics. The MIC was determined to be the lowest 
concentration of antibiotic that inhibited bacterial growth detected at A600.  
3.4. Time-Kill Analyses 
Time-kill analyses were carried out as described [27]. Two strains, the CA-MRSA USA300 strain 
TCH1516,  and  the  HA-MRSA  Sanger  252  were  prepared  as  described  above  for  MIC  assays  to  
an A600 = 0.4 in phosphate-buffered saline in 5 mL polystyrene Falcon tubes. The tubes contained the 
vehicle control (DMSO), compound 1 or compound 2, vancomycin or gentamicin at 1×  or 10×  MIC. 
The MICs against TCH1516 were 2 µg/mL, 1.5 µg/mL, 2 µg/mL and 0.5 µg/mL, respectively for 
compound 1, 2, vancomycin and gentamicin. For Sanger 252, MICs were 2 µ g/mL for compounds 1, 2, 
and vancomycin and 1.5 µg/mL for gentamicin. Bacteria were added to the tubes at 5 ×  10
5 cfu/mL 
in 4 mL and were incubated in a shaking incubator at 37 ° C. Aliquots from each tube were removed 
at 0, 2 and 4 h and were serially diluted in phosphate-buffered saline and plated on Todd-Hewitt  
agar (Hardy Diagnostics, Santa Maria, CA, USA) in the absence of antibiotics. Viable colonies were 
enumerated  after  24  h  at  37  ° C  with  a  limit  of  detection  for  the  time-kill  assay  of  40  cfu/mL.  
The 0, 2, and 4 h time points were plotted to best show the early kinetics of antibiotic activities. 
3.5. Effect of Human Serum on Antibiotic Activity 
The  MIC  in  the  presence  of  20%  pooled  human  serum  was  completed  similar  to  the  broth 
microdilution assays described above except that resazurin (Sigma-Aldrich, St. Louis, MO, USA) was 
added at a final testing concentration of 0.675 mg/mL to assess bacterial growth. Plates were covered 
with foil and incubated for 24 h with shaking at 37 ° C. After incubation, plates were assessed visually 
for color change from blue to pink to indicate bacterial growth. The MIC in the presence of 20% serum 
was  determined  to  be  the  lowest  antibiotic  concentration  that  did  not  induce  a  blue  to  pink 
color change. 
3.6. Antiproliferative Bioassay: Test for Cytotoxicity 
Aliquots of HCT-116 human colon adenocarcinoma cells were transferred to 96-well plates and 
incubated overnight at 37 ° C in 5% CO2/air. Test compounds were added to the plates in DMSO and 
serially diluted. The plates were then further incubated for another 72 h, and at the end of this period, a 
CellTiter  96  Aqueous  non-radioactive  cell  proliferation  assay  (Promega)  was  used  to  assess  cell 
viability. Inhibition concentration (IC50) values were deduced from the bioreduction of MTS/PMS by 
living cells into a formazan product. MTS/PMS was first applied to the sample wells, followed by 
incubation  for  3  h.  Etoposide  (Sigma;  IC50  =  1.549  mM)  and  DMSO  (solvent)  were  used  as  the Mar. Drugs 2011, 9  
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positive and negative controls in this assay. The quantity of the formazan product (in proportion to the 
number of living cells) in each well was determined by the Molecular Devices Emax microplate reader 
set to 490 nm wavelength. IC50 values were calculated using the analysis program Prism. 
4. Conclusions 
Complex meroterpenoids produced by terrestrial and marine-derived actinomycetes are promising 
candidates  for  drug  discovery  as  antibacterial  and  anti-tumor  agents.  Early  reports  showed  that 
napyradiomycins from terrestrial species had activities against many Gram-positive as well as some 
anaerobic bacteria [10]. Here we show that two different derivatives from this class, 1 (A80915A) and 
2  (A80915B),  a  diazoketone  derivative,  have  excellent  antibacterial  activities  against  a  panel  of 
contemporary HA- and CA-MRSA strains as well as clinically relevant glycopeptide-intermediate and 
vancomycin-resistant  strains.  Our  results  also  defined  rapid  bactericidal  kinetics  of  these 
two derivatives  against  MRSA.  These  studies  highlight  the  napyradiomycin  pharmacophore  as 
a potential therapeutic for drug-resistant clinical strains of MRSA. Clearly, the napyradiomycins will 
require significant future SAR studies to reduce cytotoxic activities and enhance anti-MRSA activities 
and bioavailability. It would also be important to define the molecular target of these compounds. 
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